All In Biotech

NDA 020822 · Abbvie

Celexa

Citalopram Hydrobromide · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Apr 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Jul 17, 1998

Approved uses

1

Original approval plus efficacy supplements

Registered trials

220

32 Phase 3, 6 recruiting

FAERS reports

114,378

86,497 serious, 15,414 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short -term studies . Closely m onitor all antidepressant-treated patients for clinical worsening , and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . CELEXA is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal though t s and behaviors ( 5.1 ) . CELEXA is not approved for use in pediatric patients ( 8.4 ) .

What it is approved for

From the label in effect Oct 9, 2023.

CELEXA is indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14 )] . CELEXA is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD) in adults ( 1 ).

Mechanism: The mechanism of action of citalopram is unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • CELEXA · CITALOPRAM HYDROBROMIDE EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB
  • CELEXA · CITALOPRAM HYDROBROMIDE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
  • CELEXA · CITALOPRAM HYDROBROMIDE EQ 60MG BASE · TABLET, ORAL · Discontinued
  • CELEXA · CITALOPRAM HYDROBROMIDE EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Citalopram Hydrobromide" as an intervention, any sponsor and status, largest first.

All 220 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue7,613
  • nausea7,137
  • drug ineffective6,331
  • diarrhoea5,443
  • headache5,402
  • dizziness4,850
  • pain4,821
  • fall4,768
  • anxiety4,682
  • dyspnoea4,671
  • toxicity to various agents4,505
  • off label use4,449

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,488
20051,270
20061,099
20071,009
2008964
20091,680
20102,609
20113,343
20124,660
20136,242
20147,587
20159,711
20169,757
20178,509
20189,026
20199,163
20207,577
20216,260
20225,139
20235,111
20244,489
20254,713
20262,966

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Celexa (Citalopram Hydrobromide)

2024 spending

$2.6M

Beneficiaries

949

4,196 claims

Per beneficiary

$2,695

$9.18 per unit

View as table
YearSpending
2020$3,538,886
2021$3,266,502
2022$3,064,998
2023$2,809,667
2024$2,557,095

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 10 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.